Serum CA19-9 is a Significant Predictor among Preoperative Parameters for Early Recurrence after Resection of Pancreatic Adenocarcinoma

被引:124
|
作者
Sugiura, Teiichi [1 ]
Uesaka, Katsuhiko [1 ]
Kanemoto, Hideyuki [1 ]
Mizuno, Takashi [1 ]
Sasaki, Keiko [2 ]
Furukawa, Hiroyoshi [3 ]
Matsunaga, Kazuya [1 ]
Maeda, Atsuyuki [1 ]
机构
[1] Shizuoka Canc Ctr, Div Hepatobiliary Pancreat Surg, Shizuoka 4118777, Japan
[2] Shizuoka Canc Ctr, Div Pathol, Shizuoka 4118777, Japan
[3] Shizuoka Canc Ctr, Div Diagnost Radiol, Shizuoka 4118777, Japan
关键词
Pancreatic cancer; CA19-9; Early recurrence; GEMCITABINE-BASED CHEMORADIATION; COMPUTED-TOMOGRAPHY; RESECTABLE ADENOCARCINOMA; BILIARY DRAINAGE; TUMOR-MARKER; CA-19-9; SURVIVAL; CHEMOTHERAPY; CANCER; THERAPY;
D O I
10.1007/s11605-012-1859-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To evaluate the preoperative factors predictive of postoperative early recurrence in patients with resected pancreatic cancer focusing on the serum CA19-9 value. One hundred fifty-four patients undergoing surgical resection for pancreatic cancer were enrolled in this study. Univariate and multivariate analyses were performed to determine the predictors of early recurrence which was defined as relapse within 6 months after surgery. On ROC curve analysis, the cutoff value of CA19-9 was determined to be 100 U/ml. Of 73 patients with CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml, 39 (53 %) had early recurrence. In contrast, only 9 of 81 patients (11 %) with CA19-9 value < 100 U/ml developed a recurrence at an early period (p < 0.001). Multivariate analysis revealed that CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml (odds ratio, 11.2) were significant predictors of early recurrence. The overall 3- and 5-year survival rates and median survival times were 47.3 %, 40.1 %, and 31 months in patients with CA19-9 value < 100 U/ml and 21.2 %, 9.4 %, and 16 months in patients with CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml (p < 0.001). A preoperative CA19-9 value a parts per thousand yenaEuro parts per thousand 100 U/ml was a significant predictor of early recurrence and a poor prognosis after resection for pancreatic adenocarcinoma.
引用
收藏
页码:977 / 985
页数:9
相关论文
共 50 条
  • [41] Is a Preoperative Assessment of the Early Recurrence of Pancreatic Cancer Possible after Complete Surgical Resection?
    La Torre, Marco
    Nigri, Giuseppe
    lo Conte, Annalisa
    Mazzuca, Federica
    Tierno, Simone Maria
    Salaj, Lona
    Marchetti, Paolo
    Ziparo, Vincenzo
    Ramacciato, Giovanni
    GUT AND LIVER, 2014, 8 (01) : 102 - 108
  • [42] Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9
    Li, Dengfeng
    Peng, Qing
    Wang, Leyao
    Cai, Wei
    Liang, Meng
    Liu, Siyun
    Ma, Xiaohong
    Zhao, Xinming
    EUROPEAN RADIOLOGY, 2024, 34 (01) : 509 - 524
  • [43] Prognostic Value of Serum Tumor Antigen CA19-9 After Curative Resection of Colorectal Cancer
    Park, In Ja
    Choi, Gyu-Seog
    Jun, Soo Han
    ANTICANCER RESEARCH, 2009, 29 (10) : 4303 - 4308
  • [44] Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma
    Xu, Hua-Xiang
    Liu, Liang
    Xiang, Jin-Feng
    Wang, Wen-Quan
    Qi, Zi-Hao
    Wu, Chun-Tao
    Liu, Chen
    Long, Jiang
    Xu, Jin
    Ni, Quan-Xing
    Yu, Xian-Jun
    SURGERY, 2017, 161 (02) : 373 - 384
  • [45] Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adenocarcinoma: A prospective multicenter cohort study
    Buchholz, Malte
    Lausser, Ludwig
    Schenk, Miriam
    Earl, Julie
    Lawlor, Rita T.
    Scarpa, Aldo
    Sanjuanbenito, Alfonso
    Carrato, Alfredo
    Malats, Nuria
    Tjaden, Christine
    Giese, Nathalia A.
    Buechler, Markus
    Hackert, Thilo
    Kestler, Hans A.
    Gress, Thomas M.
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2025, 13 (03) : 353 - 363
  • [46] Preoperative serum CA19-9 predicts postoperative pancreatic fistula in PDAC patients: retrospective analysis at a single institution
    Sugita, Hiroki
    Okabe, Hirohisa
    Ogawa, Daisuke
    Hirao, Hiroki
    Kuroda, Daisuke
    Taki, Katsunobu
    Tomiyasu, Shinjiro
    Hirota, Masahiko
    BMC SURGERY, 2022, 22 (01)
  • [47] Prognostic impact of the ratio of preoperative CA19-9 to liver enzyme levels in pancreatic cancer patients with jaundice (predictability of combined CA19-9/AST and CA19-9/γ-GGT for jaundiced PDAC patients)
    Huang, Xumin
    Lu, Zipeng
    Zhang, Kai
    Wang, Guangfu
    Cai, Baobao
    Wu, Pengfei
    Yin, Jie
    Miao, Yi
    Jiang, Kuirong
    PANCREATOLOGY, 2021, 21 (06) : 1092 - 1101
  • [48] Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma?
    Wang, Jun-Ke
    Hu, Hai-Jie
    Shrestha, Anuj
    Ma, Wen-Jie
    Yang, Qin
    Liu, Fei
    Cheng, Nan-Sheng
    Li, Fu-Yu
    ONCOTARGET, 2017, 8 (28) : 45335 - 45344
  • [49] Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma
    Cai, Wen-Ke
    Lin, Jia-Ji
    He, Gong-Hao
    Wang, Hua
    Lu, Jun-Hua
    Yang, Guang-Shun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (11): : 7890 - 7898
  • [50] The value of CA19-9 and MRI features in the preoperative differential diagnosis of pancreatic ductal adenocarcinoma in periampullary carcinoma
    Zhao, Peng-Ju
    Li, Zhi-Yu
    Bi, Xin-Yu
    Zhang, Ye-Fan
    Xu, Bo-Wen
    Wei, Zhi-Cheng
    Ye, Feng
    Chang, Jian-Ping
    ABDOMINAL RADIOLOGY, 2025,